Immunosuppressant neurotoxicity in rat brain models: Oxidative stress and cellular metabolism

Chemical Research in Toxicology

Volumn 23, Issue 3, 2010, Pages 608-619

  Klawitter, Jelena ^a,b   Gottschalk, Sven ^b,c   Hainz, Carsten ^b   Leibfritz, Dieter ^b   Christians, Uwe ^a   Serkova, Natalie J ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b UNIVERSITY OF BREMEN   (Germany)

^c UNIVERSITY OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; EVEROLIMUS; NUCLEOSIDE TRIPHOSPHATE; RAPAMYCIN; REACTIVE OXYGEN METABOLITE;

ANAEROBIC GLYCOLYSIS; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN CELL; CELL METABOLISM; CITRIC ACID CYCLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENERGY METABOLISM; ENERGY YIELD; ENZYME SYNTHESIS; GLIOMA CELL; GLUCOSE METABOLISM; MITOCHONDRION; NERVE CELL CULTURE; NEUROTOXICITY; NEWBORN; NONHUMAN; OXIDATIVE STRESS; RAT;

ANIMALS; ASTROCYTES; BRAIN; CELL LINE, TUMOR; CELLS, CULTURED; CYCLOSPORINE; IMMUNOSUPPRESSIVE AGENTS; OXIDATIVE STRESS; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; SIROLIMUS;

RATTUS;

EID: 77949352391     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx900351q     Document Type: Article

References (61)

1. Kahan, B. D. (1992) Immunosuppressive therapy. Curr. Opin. Immunol. 4, 553-560.
2. Borel, J. F., Baumann, G., Chapman, I., Donatsch, P., Fahr, A., Mueller, E. A., and Vigouret, J. M. (1996) In vivo pharmacological effects of ciclosporin and some analogues. AdV. Pharmacol. 35, 115-246.
3. Aramburu, J., Rao, A., and Klee, C. B. (2000) Calcineurin: from structure to function. Curr. Top. Cell Regul. 36, 237-295.
4. Serkova, N. J., Christians, U., and Benet, L. Z. (2004) Biochemical mechanisms of cyclosporine neurotoxicity. Mol. InterVentions 4, 97-107.
5. Atkinson, K., Biggs, J., Darveniza, P., Boland, J., Concannon, A., and Dodds, A. (1984) Cyclosporine-associated central-nervous-system toxicity after allogeneic bone-marrow transplantation. N. Engl. J. Med. 310, 527.
6. Adams, D. H., Ponsford, S., Gunson, B., Boon, A., Honigsberger, L., Williams, A., Buckels, J., Elias, E., and McMaster, P. (1987) Neurological complications following liver transplantation. Lancet 1, 949-951.
7. Gijtenbeek, J. M., van den Bent, M. J., and Vecht, C. J. (1999) Cyclosporine neurotoxicity: A review. J. Neurol. 246, 339-346.
8. Hauben, M. (1996) Cyclosporine neurotoxicity. Pharmacotherapy 16, 576-583.
9. Crompton, M., Barksby, E., Johnson, N., and Capano, M. (2002) Mitochondrial intermembrane junctional complexes and their involvement in cell death. Biochimie 84, 143-152.
10. Serkova, N., Litt, L., James, T. L., Sadee, W., Leibfritz, D., Benet, L. Z., and Christians, U. (1999) Evaluation of individual and combined neurotoxicity of the immunosuppressants cyclosporine and sirolimus by in vitro multinuclear NMR spectroscopy. J. Pharmacol. Exp. Ther. 289, 800-806.
11. Serkova, N., Donohoe, P., Gottschalk, S., Hainz, C., Niemann, C. U., Bickler, P. E., Litt, L., Benet, L. Z., Leibfritz, D., and Christians, U. (2002) Comparison of the effects of cyclosporin a on the metabolism of perfused rat brain slices during normoxia and hypoxia. J. Cereb. Blood Flow Metab. 22, 342-352.
12. Serkova, N., Jacobsen, W., Niemann, C. U., Litt, L., Benet, L. Z., Leibfritz, D., and Christians, U. (2001) Sirolimus, but not the structurally related RAD (everolimus), enhances the negative effects of cyclosporine on mitochondrial metabolism in the rat brain. Br. J. Pharmacol. 133, 875-885.
13. Wolf, A., Trendelenburg, C. F., Diez-Fernandez, C., Prieto, P., Houy, S., Trommer, W. E., and Cordier, A. (1997) Cyclosporine A-induced oxidative stress in rat hepatocytes. J. Pharmacol. Exp. Ther. 280, 1328-1334.
14. Andres, D., Sanz, N., Zaragoza, A., Alvarez, A. M., and Cascales, M. (2000) Changes in antioxidant defence systems induced by cyclosporine A in cultures of hepatocytes from 2-and 12-month-old rats. Biochem. Pharmacol. 59, 1091-1100.
15. Serkova, N., and Christians, U. (2003) Transplantation: Toxicokinetics and mechanisms of toxicity of cyclosporine and macrolides. Curr. Opin. InVest. Drugs 4, 1287-1296.
16. Morath, C., Arns, W., Schwenger, V., Mehrabi, A., Fonouni, H., Schmidt, J., and Zeier, M. (2007) Sirolimus in renal transplantation. Nephrol., Dial., Transplant. 22 (Suppl. 8), viii61-viii65.
17. Augustine, J. J., and Hricik, D. E. (2004) Experience with everolimus. Transplant Proc. 36, 500S-503S.
18. Serkova, N. J., and Christians, U. (2005) Biomarkers for toxicodynamic monitoring of immunosuppressants: NMR-based quantitative metabonomics of the blood. Ther. Drug Monit. 27, 733-737.
19. Kahan, B. D. (2000) Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study. The Rapamune US Study Group. Lancet 356, 194-202.
20. Kahan, B. D., and Kramer, W. G. (2001) Median effect analysis of efficacy versus adverse effects of immunosuppressants. Clin. Pharmacol. Ther. 70, 74-81.
21. Serkova, N., Litt, L., Leibfritz, D., Hausen, B., Morris, R. E., James, T. L., Benet, L. Z., and Christians, U. (2000) The novel immunosuppressant SDZ-RAD protects rat brain slices from cyclosporine-induced reduction of high-energy phosphates. Br. J. Pharmacol. 129, 485-492.
22. Gordon, G. R., Choi, H. B., Rungta, R. L., Ellis-Davies, G. C., and MacVicar, B. A. (2008) Brain metabolism dictates the polarity of astrocyte control over arterioles. Nature 456, 745-749.
23. Rouach, N., Koulakoff, A., Abudara, V., Willecke, K., and Giaume, C. (2008) Astroglial metabolic networks sustain hippocampal synaptic transmission. Science 322, 1551-1555.
24. Goya, L., Feng, P. T., Aliabadi, S., and Timiras, P. S. (1996) Effect of growth factors on the in vitro growth and differentiation of early and late passage C6 glioma cells. Int. J. DeV. Neurosci. 14, 409-417.
25. Vernadakis, A., Kentroti, S., Brodie, C., Mangoura, D., and Sakellaridis, N. (1991) C-6 glioma cells of early passage have progenitor properties in culture. AdV. Exp. Med. Biol. 296, 181-195.
26. Easton, J. B., and Houghton, P. J. (2006) mTOR and cancer therapy. Oncogene 25, 6436-6446.
27. Nicholson, J. K., and Wilson, I. D. (2003) Opinion: understanding 'global' systems biology: Metabonomics and the continuum of metabolism. Nat. ReV. Drug DiscoVery 2, 668-676.
28. Nicholson, J. K., Lindon, J. C., and Holmes, E. (1999) 'Metabonomics': Understanding the metabolic responses of living systems to patho-physiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 29, 1181-1189.
29. Nicholson, J. K., and Lindon, J. C. (2008) Systems biology: Metabonomics. Nature 455, 1054-1056.
30. Coen, M., Holmes, E., Lindon, J. C., and Nicholson, J. K. (2008) NMRbased metabolic profiling and metabonomic approaches to problems in molecular toxicology. Chem. Res. Toxicol. 21, 9-27.
31. Booher, J., and Sensenbrenner, M. (1972) Growth and cultivation of dissociated neurons and glial cells from embryonic chick, rat and human brain in flask cultures. Neurobiology 2, 97-105.
32. Christians, U., Gottschalk, S., Miljus, J., Hainz, C., Benet, L. Z., Leibfritz, D., and Serkova, N. (2004) Alterations in glucose metabolism by cyclosporine in rat brain slices link to oxidative stress: Interactions with mTOR inhibitors. Br. J. Pharmacol. 143, 388-396.
33. Bass, D. A., Parce, J. W., Dechatelet, L. R., Szejda, P., Seeds, M. C., and Thomas, M. (1983) Flow cytometric studies of oxidative product formation by neutrophils: A graded response to membrane stimulation. J. Immunol. 130, 1910-1917.
34. Klawitter, J., Kominsky, D. J., Brown, J. L., Klawitter, J., Christians, U., Leibfritz, D., Melo, J. V., Eckhardt, S. G., and Serkova, N. J. (2009) Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells. Br. J. Pharmacol. 158, 588-600.
35. Kominsky, D. J., Klawitter, J., Brown, J. L., Boros, L. G., Melo, J. V., Eckhardt, S. G., and Serkova, N. J. (2009) Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells. Clin. Cancer Res. 15, 3442-3450.
36. Klawitter, J., Anderson, N., Klawitter, J., Christians, U., Leibfritz, D., Eckhardt, S. G., and Serkova, N. J. (2009) Time-dependent effects of imatinib in human leukaemia cells: A kinetic NMR-profiling study. Br. J. Cancer 100, 923-931.
37. Zwingmann, C., Leibfritz, D., and Hazell, A. S. (2003) Energy metabolism in astrocytes and neurons treated with manganese: Relation among cell-specific energy failure, glucose metabolism, and intercellular trafficking using multinuclear NMR-spectroscopic analysis. J. Cereb. Blood Flow Metab. 23, 756-771.
38. Zwingmann, C., Chatauret, N., Leibfritz, D., and Butterworth, R. F. (2003) Selective increase of brain lactate synthesis in experimental acute liver failure: Results of a [H-C] nuclear magnetic resonance study. Hepatology 37, 420-428.
39. Goa, J. (1953) A micro biuret method for protein determination; determination of total protein in cerebrospinal fluid. Scand. J. Clin. Lab. InVest. 5, 218-222.
40. Beal, M. F., Brouillet, E., Jenkins, B., Henshaw, R., Rosen, B., and Hyman, B. T. (1993) Age-dependent striatal excitotoxic lesions produced by the endogenous mitochondrial inhibitor malonate. J. Neurochem. 61, 1147-1150.
41. Simonian, N. A., and Coyle, J. T. (1996) Oxidative stress in neurodegenerative diseases. Annu. ReV. Pharmacol. Toxicol. 36, 83-106.
42. Gummert, J. F., Ikonen, T., and Morris, R. E. (1999) Newer immunosuppressive drugs: A review. J. Am. Soc. Nephrol. 10, 1366-1380.
43. Halliwell, B. (1992) Reactive oxygen species and the central nervous system. J. Neurochem. 59, 1609-1623.
44. Miller, B. L. (1991) A review of chemical issues in 1H NMR spectroscopy: N-Acetyl-L-aspartate, creatine and choline. NMR Biomed. 4, 47-52.
45. Sonnewald, U., Therrien, G., and Butterworth, R. F. (1996) Portacaval anastomosis results in altered neuronsAstrocytic metabolic trafficking of amino acids: Evidence from 13C-NMR studies. J. Neurochem. 67, 1711-1717.
46. Tsai, G., and Coyle, J. T. (1995) N-Acetylaspartate in neuropsychiatric disorders. Prog. Neurobiol. 46, 531-540.
47. Brooks, W. M., Stidley, C. A., Petropoulos, H., Jung, R. E., Weers, D. C., Friedman, S. D., Barlow, M. A., Sibbitt, W. L., Jr., and Yeo, R. A. (2000) Metabolic and cognitive response to human traumatic brain injury: A quantitative proton magnetic resonance study. J. Neurotrauma 17, 629-640.
48. Shuto, H., Kataoka, Y., Fujisaki, K., Nakao, T., Sueyasu, M., Miura, I., Watanabe, Y., Fujiwara, M., and Oishi, R. (1999) Inhibition of GABA system involved in cyclosporine-induced convulsions. Life Sci. 65, 879-887.
49. Tominaga, K., Yamauchi, A., Shuto, H., Niizeki, M., Makino, K., Oishi, R., and Kataoka, Y. (2001) Ovariectomy aggravates convulsions and hippocampal gamma-aminobutyric acid inhibition induced by cyclosporin A in rats. Eur. J. Pharmacol. 430, 243-249.
50. Genova, M. L., Pich, M. M., Bernacchia, A., Bianchi, C., Biondi, A., Bovina, C., Falasca, A. I., Formiggini, G., Castelli, G. P., and Lenaz, G. (2004) The mitochondrial production of reactive oxygen species in relation to aging and pathology. Ann. N. Y. Acad. Sci. 1011, 86-100.
51. Serkova, N., Christians, U., Flogel, U., Pfeuffer, J., and Leibfritz, D. (1997) Assessment of the mechanism of astrocyte swelling induced by the macrolide immunosuppressant sirolimus using multinuclear nuclear magnetic resonance spectroscopy. Chem. Res. Toxicol. 10, 1359-1363.
52. Plas, D. R., and Thompson, C. B. (2005) Akt-dependent transformation: There is more to growth than just surviving. Oncogene 24, 7435-7442.
53. Edinger, A. L., Linardic, C. M., Chiang, G. G., Thompson, C. B., and Abraham, R. T. (2003) Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells. Cancer Res. 63, 8451-8460.
54. Serkova, N., Hausen, B., Berry, G. J., Jacobsen, W., Benet, L. Z., Morris, R. E., and Christians, U. (2000) Tissue distribution and clinical monitoring of the novel macrolide immunosuppressant SDZ-RAD and its metabolites in monkey lung transplant recipients: interaction with cyclosporine. J. Pharmacol. Exp. Ther. 294, 323-332.
55. Feeney, C. J., Frantseva, M. V., Carlen, P. L., Pennefather, P. S., Shulyakova, N., Shniffer, C., and Mills, L. R. (2008) Vulnerability of glial cells to hydrogen peroxide in cultured hippocampal slices. Brain Res. 1198, 1-15.
56. Panwalkar, A., Verstovsek, S., and Giles, F. J. (2004) Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer 100, 657-666.
57. Vignot, S., Faivre, S., Aguirre, D., and Raymond, E. (2005) mTORtargeted therapy of cancer with rapamycin derivatives. Ann. Oncol. 16, 525-537.
58. Hjelmeland, A. B., Lattimore, K. P., Fee, B. E., Shi, Q., Wickman, S., Keir, S. T., Hjelmeland, M. D., Batt, D., Bigner, D. D., Friedman, H. S., and Rich, J. N. (2007) The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion. Mol. Cancer Ther. 6, 2449-2457.
59. Warburg, O. (1956) On the origin of cancer cells. Science 123, 309-314.
60. Szatrowski, T. P., and Nathan, C. F. (1991) Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res. 51, 794-798.
61. Trachootham, D., Zhou, Y., Zhang, H., Demizu, Y., Chen, Z., Pelicano, H., Chiao, P. J., Achanta, G., Arlinghaus, R. B., Liu, J., and Huang, P. (2006) Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 10, 241-252.